NCT06422221

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Name: Clinical Trial NCT06422221
Creator: University of Santiago de Compostela
Keywords: Bacteremia,Endocarditis, Clindamycin, Phase 4, drug, clinical trial, Spain

University of Santiago de Compostela·Phase 4·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Bacteremia,Endocarditis
Drug/Device/Intervention: Clindamycin
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: University of Santiago de Compostela
Location: Santiago De Compostela, Spain

Timeline & enrollment

Phase: Phase 4
Start date: May 14, 2024
End date: Jun 30, 2025
Enrollment: 150 participants

Primary outcome

Bacteremia in participants receiving a prophylactic dosage with oral doxycyclin

Summary

Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at risk of infective endocarditis, expert committees continue to publish recommendations for antibiotic prophylactic regimens. The last American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines include several important changes, highlighting that clindamycin (CLI) is no longer recommended as an alternative to amoxicillin in those allergic to penicillin. This new project aims to evaluate the effectiveness of oral doxycycline in preventing post-dental extraction bloodstream infection.

ICD-10 classifications

Candidal endocarditisAcute endocarditis, unspecifiedAcute and subacute infective endocarditisAcute and subacute endocarditisMyocarditis in bacterial diseases classified elsewhere

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06422221
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06422221 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Santiago de Compostela and is currently Not yet recruiting. The study focuses on Bacteremia,Endocarditis. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.